Synact Pharma, der holder til i Holte, men er noteret på Aktietorget i Sverige, har rejst dobbelt så meget som forventet i et markant overtegnet aktieudbud. Det skal hjælpe selskabet med et fase 2-studie af en lægemiddelkandidat mod gigt.
Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.
Få fuld adgang til vores kvalitetsjournalistik med et prøveabonnement.
Image Analysis Specialist - Visiopharm
Clinical Trial Manager - Genmab
Manager Process Validation - Ascendis Pharma
Senior Manager Downstream Manufacturing - Ascendis Pharma
Senior Radiochemist - Y-mAbs
QA Manager GCP - Genmab
QC Manager with project coordination and transfer experience - Ascendis Pharma
QA Professional – Drug Substance and Analytical Testing
Senior Clinical Trial Manager - Zealand Pharma
Senior Quality Manager, Quality Systems and Compliance – Ascendis Pharma
QA Manager – Medical Devices and Combination Products - Ascendis Pharma
Sr. Manager Clinical Quality Assurance - Ascendis Pharma
Clinical Research Scientist - Genmab
Salgschef til Region Sydøst - Nomeco
Senior Manager Drug Product – Ascendis Pharma
Clinical Development Specialist - Visiopharm
QA Manager - Genmab
CMC Project Manager - Y-mAbs Therapeutics
CMC PM - Genmab
